nach oben

Medical Microbiology and Immunology

Erschienen in:

01.02.2011 | Review

The underlying mechanisms for the “isolated positivity for the hepatitis B surface antigen (HBsAg)” serological profile

verfasst von: Robério Amorim de Almeida Pondé

Erschienen in: Medical Microbiology and Immunology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

During HBV infection, four structural antigen/antibody systems are observed: hepatitis B surface antigen (HBsAg) and its antibody (anti-HBs); the pre-S antigens associated with HBsAg particles and their antibodies; the particulate nucleocapsid antigen (HBcAg) and anti-HBc; and an antigen structurally related to HBcAg, namely HBeAg and its antibody (anti-HBe). Through the examination of this antigen–antibodies system, hepatitis B infection is diagnosed and the course of the disorder may be observed. Isolated HBsAg seropositivity is a peculiar serological pattern in HBV infection observed some times in routine laboratory. In most cases is not clear how this profile should be interpreted neither its significance. This pattern, however, may be associated with some clinical and laboratorial situations of great relevance, some of which will be addressed in this article.

Chan H (2002) Changing scene in hepatitis B serology interpretation. Hosp Med 63(1):16–19PubMed

Juszczyk J (2000) Clinical course and consequences of hepatitis B infection. Vaccine 18:S23–S25CrossRefPubMed

Kao JH (2008) Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol 2(4):553–562CrossRefPubMed

Badur S, Akgun A (2001) Diagnosis of hepatitis B infections and monitoring of treatment. J Clin Virol 21:229–237CrossRefPubMed

Echevarria JM, Leon P, Pozo F (2004) Reactividad para antígeno de superfície del vírus de la hepatitis B em ausência de anticuerpos frente al antígeno de la cápside del vírus da hepatitis B: um patrón serológico atípico de dignificado diverso. Enferm Infec Microbiol Clín 22(1):6–12CrossRef

Jung M-C, Gerd RP (2002) Immunology of hepatitis B infection. Lancet 2:43–50CrossRef

Almeida R, Cardoso D (2006) Detection of HBV DNA by nested PCR in a HBsAg and anti-HBc negative blood bank donor. J Clin Virol 36(3):231–234CrossRefPubMed

Walz A, Wirth S, Hucke J, Gerner P (2009) Vertical transmission of hepatitis B virus (HBV) from mothers negative for HBV surface antigen and positive for antibody to HBV core antigen. J Infect Dis 200(8):1227–1231CrossRefPubMed

Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW (2003) Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 43:788–798CrossRefPubMed

10.

La’ulu SL, Roberts WL (2006) The analytic sensitivity and mutant detection capability os six hepatitis B surface antigen assays. Immunopathology 125:748–751

11.

Dufour R (2006) Hepatitis B surface antigen (HBsAg) assays—are they good enough for their current uses? Clin Chem 52(8):1457–1459CrossRefPubMed

12.

Hollinger FB (2007) Hepatitis B vírus genetic diversity and its impact on diagnostic assays. J Viral Hepat 14(Suppl 1):11–15CrossRefPubMed

13.

Weber B (1999) Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol 37(8):2639–2647PubMed

14.

Weber B, Taelem-Brulé N, Berger A, Simon F, Geudin M, Ritter J (2006) Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. J Virol Meth 135:109–117CrossRef

15.

Weber B (2004) The diagnostic and clinical impact on the genetic variability of the S (surface) gene of hepatitis B virus. J Lab Med 28:56–69

16.

Coleman PF (2006) Detecting hepatitis B surface antigen mutants. Em Inf Dis 12(2):198–202

17.

Gerlich W, Glebe D, Schuttler C (2007) Deficiencies in the standardization and sensitivity of diagnostic testes for hepatitis B virus. J Viral Hepat 14(1):16–21CrossRefPubMed

18.

O’Brien J (2000) Hepatitis B surface antigen: decreased need for confirmation of reactive results. Clin Chem 46:582PubMed

19.

Coleman P, Chen Y-C, Mushahwar K (1999) Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 59:19–24CrossRefPubMed

20.

Chen D, Kaplan L (2006) Performance of a new-generation Chemiluminescent Assay for hepatitis B surface antigen. Clin Chem 52(8):1592–1598CrossRefPubMed

21.

Ratman S, Stead F, Head C (1989) False-positive results with third-generation monoclonal hepatitis B surface antigen enzyme immunoassay. J Clin Microbiol 27:2102–2104

22.

Weber B, Dengler T, Berger A, Doerr H, Rabenau H (2003) Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol 41(1):135–143CrossRefPubMed

23.

Diepersloot R, Oostrom Y, Gleaves C (2000) Comparison of a chemiluminescent immunoassay with two microparticle enzyme immunoassays for detection of hepatitis B virus surface antigen. Clin Diag Lab Immunol 7(6):865–866

24.

Hou J, Liu Z, Gu F (2005) Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2(1):50–57PubMed

25.

Zuckerman JN (2006) Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:169–177CrossRefPubMed

26.

Kloster B, Kramer R, Eastlund T, Grossman B, Zarvan B (1995) Hepatitis B surface antigenemia in blood donors following vaccination. Transfusion 35:475–477CrossRefPubMed

27.

Otag F (2003) False positive HBsAg result in blood donors due to administration of three different recombinant DNA hepatitis B vaccines. Vaccine 21:3734–3737CrossRefPubMed

28.

Dow BC, Yates P, Galea G, Munro H, Buchanan I, Ferguson K (2002) Hepatitis B vaccines may be mistaken for confirmed hepatitis B surface antigen-positive blood donors. Vox Sang 82:15–17CrossRefPubMed

29.

Lunn ER, Hoggarth BJ, Cook WJ (2000) Prolonged hepatitis B surface antigenemia after vaccination. Pediatrics 105(6):E81CrossRefPubMed

30.

Challapalli M, Slosar M, Vasa R, Cunningham D (1993) Brief surface antigenemia in newborn infants vaccinated with hepatitis B vaccine. Pediatr Infect Dis J 12(10):878–879CrossRefPubMed

31.

Bernstein SR, Krieger P, Puppolo B, Castello M (1994) Incidence and duration of hepatitis B surface antigenemia after neonatal hepatitis B immunization. J Pediatr 125(4):621–622CrossRefPubMed

32.

Weintraub W, Khamaysi N, Elena H (1994) Transient surface antigenemia in newborn infants vaccinated with engerix B: Occurrence and duration. Pediatr Infect Dis J 13(10):931–933CrossRefPubMed

33.

Koksal N, Altinkaya N, Perk Y (1996) Transient hepatitis B surface antigenemia after neonatal hepatitis B. Acta Pediatr 85(12):1501–1502CrossRef

34.

Milich D, McLachlan A (1986) The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234(4782):1398–1401CrossRefPubMed

35.

Milich D, Sallberg M, Maruyama T (1995) The humoral immune response in acute and chronic hepatitis B virus infection. Springer Semin Immunopathol 17:140–166CrossRef

36.

Chen M, Sallberg M, Hughes J, Jones J, Guidotti L, Chisari F, Billaud J-N, Milich D (2005) Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 79:3016–3027CrossRefPubMed

37.

Diepolder HM, Jung M-C, Wierenga E, Hoffmann RM, Zachoval R, Gerlach T, Scholz S, Heavner G, Riethmuller G, Pape G (1996) Anergic TH1 clones specific for hepatitis B virus core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro. J Virol 70:7540–7548PubMed

38.

Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, Frosner G, Will H, Pape GR (1995) Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 69:3358–3368PubMed

39.

Lee JH, Paglieroni G, Holland PV, Zeldis JB (1992) Chronic hepatitis B virus infection in an anti-HBc-nonreactive blood donor: variant virus or defective immune response? Hepatology 16(1):24–30CrossRefPubMed

40.

Laperche S, Guitton C, Smilovici C, Courouce A (2001) Blood donors infected with the hepatitis B virus but persistently lacking antibodies to the hepatitis B core antigen. Vox Sang 80:90–94CrossRefPubMed

41.

Gotoh K, Mima S, Uchida T, Shikata T, Yoshizawa K, Irie M, Mizui M (1995) Nucleotide sequence of hepatitis B virus isolated from subjects without serum anti-hepatitis B core antibody. J Med Virol 46:201–206CrossRefPubMed

42.

Ni YH, Hsu HY, Chang MH, Chen DS, Lee CY (1993) Absence or delayed appearance of hepatitis B core antibody on chronic hepatitis B surface antigen carrier children. J Hepatology 17(2):150–154CrossRef

43.

Milich DR, Chen MK, Hughes JL, Jones J (1998) The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 160:2013–2021PubMed

44.

Wang JS, Chen H, Zhu Q-R (2005) Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers. World J Gastroenterol 11(23):3582–3585PubMed

45.

Zoulim F, Zhang X, Pichoud C, Trepo C (1996) Heterogeneity oh hepatitis B virus (HBV) core gene in a patient with HBV-associated cirrhosis and serum negativity for anti-HBc. J Hepatol 24:15–160CrossRef

46.

Bruss V (2007) Hepatitis B virus morphogenesis. World J Gastroenterol 13(1):65–73PubMed

47.

Beck J, Nassal M (2007) Hepatitis B replication. World J Gastroenterol 13(1):48–64PubMed

48.

Kreutz C (2002) Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med 1(6):113–143CrossRef

49.

Fiodarlisi G, Primi D, Tanzi E, Magni E, Incarbione C, Zanetti A, Cariani E (1994) Hepatitis B vírus C gene heterogeneity in a familial cluster of anti-HBc negative chronic carriers. J Med Virol 42(2):109–114CrossRef

50.

Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, Pilli M, Fowler P, Giuberti T, Chisari F, Fiaccadori F (1991) Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 88:214–222CrossRefPubMed

51.

Fouillot N, Tiouzeau S, Rossignol J, Jean-Jean O (1993) Translation of the hepatitis B virus P gene by ribosomal scanning as an alternative to internal initiation. J Virol 8:4886–4893

52.

Marinos G, Torre F, Gunther S, Thomas M, Will H, Williams R, Naoumov N (1996) Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. Gastroenterology 1:183–192CrossRef

53.

Kramvis A, Kew MC (1999) The core promoter of hepatitis B virus. J Viral Hepat 6(6):415–427CrossRefPubMed

54.

Honigwachs J, Faktor O, Dikstein R, Shaul Y, Laub O (1989) Liver-specific expression of hepatitis B virus is determined by the combined action of the core gene promoter and the enhancer. J Virol 2:919–924

55.

Lopez-Cabrera M, Letovsky J, Hu K, Siddiqui A (1991) Transcriptional factor C-EBP binds to and transactivates the enhancer element II of the hepatitis B virus. Virology 2:825–829CrossRef

56.

Uchida T, Shimogima S, Gotoh K, Shikata T, Mima S (1994) Pathology of livers infections with ‘silent’ hepatitis B virus mutant. Liver 14:251–256PubMed

57.

Fukuda R, Ishimura N, Kushiyama Y, Moriyama N, Ishihara M, Chowdhury A, Tokuda A, Sakai S, Akagi S, Watanabe M, Fukumoto S (1996) Hepatitis B Vírus with ‘X’ gene mutation is associated with the majority of serologically ‘silent’ non-B, non-C chronic hepatitis. Microbiol Immunol 40:481–488PubMed

58.

Coursaget P, Yvonnet B, Bourdil C, Mevelec MN, Adamowicz P, Barres JL, Chotard J, N’Doye R, Diop Mar I, Chiron JP (1987) HBsAg positive reactivity in man not due to hepatitis B virus. Lancet 2:1354–1358CrossRefPubMed

59.

Echevarria JM, Leon P, Domingo CJ, López JA, Echevarria JE, Contreras G, Fuertes A (1991) Characterization of HBV2-like infections in Spain. J Med Virol 33(4):240–247CrossRefPubMed

60.

Sheffield JS, Laibl VR, Roberts SW, Wendel GD (2005) False positive results for the AUSZYME monoclonal test (Letter). Am Col Obst and Gyn 105(2):449–450CrossRef

61.

Ratnam S, Stead F, Head CB (1989) False-positive results with third generation monoclonal hepatitis B surface antigen enzyme immunoassay. J Clin Microbiol 27:2102–2104PubMed

62.

Wu J-S, Ko Y-C, Liu W-T (1988) Hepatitis B virus type 2 (letter). Lancet 1:990

63.

Echevarria JM, León P, Domingo CJ, López JA (1988) Atypical hepatitis B vírus in Spain? (Letter). Lancet 2:1315–1316CrossRefPubMed

64.

Redeker AG, Govindarajan S (1988) Possible case of HBV2 infection (letter). Lancet 1:656CrossRefPubMed

65.

Bouisson Y, Coursaget P, Bourdil C, Schill H, Joussement M, Lolinié C (1990) Hepátitis B virus type 2 infection in France. Res in Virol 141:365–371CrossRef

66.

Valliammai T, Echevarria JM, Léon P, Tusets C, Harrison TJ (1995) Amplification and sequence analysis of the precore and core region of the HBV genome from sera of Spanish patients with HBV2-like infectiona. J Med Virol 36:375–379CrossRef

67.

Lazizi Y, Dubreuil P, Pillot J (1992) Excess HBcAg antibody-negative chronic hepatitis B virus carriers. Hepatology 17(6):966–970

68.

Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR (1993) The serology of chronic hepatitis B infection revisited. J Clin Invest 91:2586–2595CrossRefPubMed

69.

Bredehorst R, Von Wulffen H, Granato C (1985) Quantification of hepatitis B virus (HBV) core antigen in serum in the presence of antibodies do HBV core antigen: comparison with assays of serum HBV DNA, DNA polymerase and HBVe antigen. J Clin Microbiol 21:593–598PubMed

70.

Petit MA, Capel F, Pillot J (1988) Demonstration of a firm association between hepatitis B surface antigen protein bearing polymerized human albumin binding sites and core-specific determinants in serum hepatitis B viral particles. Mol Immunol 2:1279–1287

71.

Moller B, Hopf U, Stemerowicz R, Henze G, Gelderblom H (1989) HBcAg express on the surface of circulating Dane particles in patients with hepatitis B virus infection without evidence of anti-HBc formation. Hepatology 10(2):179–185CrossRefPubMed

72.

Melegari M, Jung MC, Schneider R, Santantonio T, Bagnulo S, Lchena N, Pastore G, Pape G, Scaglioni P, Villa E (1991) Conserved core protein sequences in hepatitis B vírus infected patients without anti-HBc. J Hepatol 13(2):187–191CrossRefPubMed

73.

Jung M-C, Pape GR (2002) Immunology of hepatitis B infection. Lancet 2(1):43–50CrossRef

74.

Avettand-Fenoel V, Thabut D, Katlama C, Poynard T, Thibault V (2006) Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol 44(6):2250–2253CrossRefPubMed

75.

Loriot M-A, Marcellin P, Walker F, Boyer N, Degott C, Randrianatoavina I, Benhamou JP, Erlinger S (1997) Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 27:251–258CrossRefPubMed

76.

Blackberg J, Kidd-Ljunggren K (2000) Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 33:992–997CrossRefPubMed

77.

Kleinman SH, Busch MP (2006) Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 36(Suppl 1):S23–S29CrossRefPubMed

78.

Chen C-H, Lee C-M, Wang J-H, Tung H-D, Hung C-H, Lu S-N (2004) Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gast Hepatol 16:1213–1218CrossRef

79.

Alain JP (2004) Occult hepatitis B virus infection. Transf Clin Biol 11(1):18–25CrossRef

80.

Jaroszewics J, Serrano BC, Wursthon K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M (2010) Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 52(4):514–522CrossRef

81.

Togashi H, Hashimoto C, Yokozawa J, Suzuki A, Sugahara K, Saito T, Yamaguchi I, Badawi H, Kainuma N, Aoyama M, Ohya H, Akatsuka T, Tanaka Y, Mizokami M, Kawata S (2008) What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol 49:17–24CrossRefPubMed

82.

Chiaramonte M, Stroffolini T, Ngatchu T, Rapicetta M, Lantum D, Kaptue J (1991) Hepatitis B virus infection in Camerron. A seroepidemiological survey in city school children. J Med Virol 33:95–99CrossRefPubMed

83.

Sastre A, Arino V, Gutiérrez J, León P, Echevarria JM (1991) Infección por VHB-2? Enferm Infecc Microbiol Clin 9:581–582PubMed

84.

Benito R, Bernad JM, Pérez Calvo J, Rubio MC (1992) Perfiles complatibles com infección por El VHB-2. Ver Esp Microbiol Clin 7:510–511

85.

Zou S, Stramerr SL, Notari EP, Kuhns MC, Krysztot D, Musavi F, Fang CT, Dodd RY (2009) Current incidence and residual risk of hepatitis B infection among blood donors in the United States Transfusion (abstract) [Epub ahead of print]

86.

Chongsrisawat V, Thawornsuk N, Theamboonlers A, Louisirirotchanakul S, Poovorawan Y (2006) Hepatitis B vírus DNA in unusual serological profiles of hepatitis B surface antigen-positive sera. Viral Immunol 19(4):623–629CrossRefPubMed

87.

Akhtar S, Younus M, Adil S, Hassan F, Jafri S (2005) Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan. BMC Gastroenterol 5:26. doi:10.1186/1471-230X/5/26 CrossRefPubMed

88.

Naoky C, Holck P, Wong L, Ricalde A (2008) Seroepidemiology of hepatitis B virus infection: analysis of mass screening in Hawaii. Hepatol Int 2:478–485CrossRef

Titel: The underlying mechanisms for the “isolated positivity for the hepatitis B surface antigen (HBsAg)” serological profile
verfasst von: Robério Amorim de Almeida Pondé
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Medical Microbiology and Immunology / Ausgabe 1/2011
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-010-0160-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Hidden hazards of HCV transmission

Oncomodulation by human cytomegalovirus: novel clinical findings open new roads

Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients

Monoassociation with probiotic Lactobacillus delbrueckii UFV-H2b20 stimulates the immune system and protects germfree mice against Listeria monocytogenes infection

Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses